natgillin/translations-raw huggingface dataset:
Hvis du har taget for mange MIRAPEXIN tabletter Hvis du har taget for mange MIRAPEXIN tabletter, så kontakt lægen eller skadestuen med det samme. 
If you take more MIRAPEXIN than you should If you accidentally take too many tablets, - Contact your doctor or nearest hospital casualty department immediately for advice.
Hvert blisterkort indeholder 10 depottabletter. 
Each blister strip contains 10 prolonged-release tablets.
• behandling af voksne patienter med symptomer på moderat til svær restless legs syndrom (RLS), 
- treat the symptoms of moderate to severe primary Restless Legs Syndrome in adults.
Symptomer, der ligner malignt neuroleptikasyndrom, har været set i forbindelse med pludseligt ophør med dopaminbehandling (se pkt. 
Symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy (see section 4.2).
De primære virknings-parametre var gennemsnitsændringen fra baseline af restless legs syndrom Rating Scale (IRLS) og Clinical Global Impression-Improvement (CGI-I). 
The mean change from baseline in the Restless Legs Syndrome Rating Scale (IRLS) and the Clinical Global Impression-Improvement (CGI-I) were the primary efficacy outcome measures.
I den første uge er dosis oftest 1 MIRAPEXIN tablet á 0,088 mg tre gange dagligt (svarende til 0,264 mg om dagen): 
During the first week, the usual dose is 1 tablet MIRAPEXIN 0.088 mg three times a day (equivalent to 0.264 mg daily):
Patienterne bør informeres om dette, og rådes til forsigtighed ved bilkørsel og betjening af maskiner. 
Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with MIRAPEXIN.
Kartoner indeholdende 3 eller 10 blisterkort (30 eller 100 tabletter). 
Cartons containing 3 or 10 blister strips (30 or 100 tablets).
Den daglige dosis skal deles i 3 lige store doser. 
The daily dose is administered in equally divided doses 3 times a day.
MIRAPEXIN indeholder det aktive stof pramipexol, der er en såkaldt dopaminagonist, som stimulerer specielle receptorer i hjernen (dopaminreceptorerne). 
MIRAPEXIN contains the active substance pramipexole and belongs to a group of medicines known as dopamine agonists, which stimulate dopamine receptors in the brain.
Det er ikke relevant at anvende Mirapexin depottabletter hos den pædiatriske population ved indikationen Parkinsons sygdom. 
There is no relevant use of MIRAPEXIN prolonged-release tablets in the paediatric population for the indication of Parkinson's Disease.
Alle tabletter har Boehringer Ingelheim firma symbol præget på den ene side og koden P1, P2, P3, P12, P4, P13 eller P5 på den anden side gældende for tablet styrkerne 0,26 mg, 0,52 mg, 1,05 mg, 1,57 mg, 2,1 mg, 2,62 mg og 3,15 mg. 
All tablets have the Boehringer Ingelheim company symbol embossed on one side and the codes P1, P2, P3, P12, P4, P13, or P5 on the other side, representing the tablet strengths 0.26 mg, 0.52 mg, 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg and 3.15 mg, respectively.
Almindeligste bivirkninger ved restless legs syndrom De mest almindeligt ( 5%) rapporterede bivirkninger hos patienter med restless legs syndrom, er kvalme, hovedpine, svimmelhed og træthed. 
Restless Legs Syndrome, most common adverse reactions The most commonly (≥ 5%) reported adverse drug reactions in patients with Restless Legs Syndrome treated with pramipexole were nausea, headache, dizziness and fatigue.
Det skal du vide, før du begynder at tage MIRAPEXIN 
What you need to know before you take MIRAPEXIN
1. uge 
st week
Hver tablet indeholder 0,26 mg, 0,52 mg, 1,05 mg, 1,57 mg, 2,1 mg, 2,62 mg eller 3,15 mg pramipexol som henholdsvis 0,375 mg, 0,75 mg, 1,5 mg, 2,25 mg, 3 mg, 3,75 mg eller 4,5 mg pramipexoldihydrochloridmonohydrat. 
Each tablet contains 0.26 mg, 0.52 mg, 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg, or 3.15 mg pramipexole as 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, or 4.5 mg pramipexole dihydrochloride monohydrate, respectively.
Det er almindeligt, at pramipexolbehandling er forbundet med døsighed, men det er ikke almindeligt, at det er forbundet med somnolens (søvnlignende bevidsthedssvækkelse) i dagtimerne og pludseligt opståede søvnepisoder (se også pkt. 
Pramipexole is commonly associated with somnolence and has been associated uncommonly with excessive daytime somnolence and sudden sleep onset episodes (see also section 4.4).
MIRAPEXIN påvirker nerveimpulser i hjernen, som kontrollerer kroppens bevægelser, ved at stimulere dopaminreceptorerne. 
Stimulation of the dopamine receptors triggers nerve impulses in the brain that help to control body movements.
• Ved kreatininclearance mellem 20 og 50 ml/min bør initialdosis af Mirapexin fordeles på 2 daglige doser begyndende med 0,088 mg base (0,125 mg salt) to gange dagligt svarende til 0,176 mg base (0,25 mg salt)/dag. 
In patients with a creatinine clearance between 20 and 50 ml/min, the initial daily dose of MIRAPEXIN should be administered in two divided doses, starting at 0.088 mg of base (0.125 mg of salt) twice a day (0.176 mg of base/0.25 mg of salt daily).
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE KARTON 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Folding box
Hver tablet indeholder 0,088 mg, 0,18 mg, 0,35 mg eller 0,7 mg pramipexol som henholdsvis 0,125 mg, 0,25 mg, 0,5 mg eller 1 mg pramipexoldihydrochloridmonohydrat. 
Each tablet contains 0.088 mg, 0.18 mg, 0.35 mg, or 0.7 mg pramipexole as 0.125 mg, 0.25 mg, 0.5 mg, or 1 mg pramipexole dihydrochloride monohydrate, respectively.
MIRAPEXIN 0,18 mg og MIRAPEXIN 0,35 mg er hvide, ovale og flade tabletter. 
MIRAPEXIN 0.18 mg tablets and MIRAPEXIN 0.35 mg tablets are white, of oval shape, and flat.
• Psykoser (f.eks. som ved symptomer på skizofreni) 
- Psychosis (e.g. comparable with symptoms of schizophrenia) - Vision impairment.
Et dobbeltblindet, placebokontrolleret studie med 539 patienter med tidlig Parkinsons sygdom viste, at Mirapexin depottabletter havde en bedre virkning (superior) end placebo efter 18 ugers behandling på både det primære (UPDRS del II+III score) og vigtigste sekundære (CGI-I og PGI-I responderhastigheder) endepunkter. 
In a double-blind placebo-controlled trial including a total of 517 patients with advanced Parkinson's disease who were on concomitant levodopa therapy superiority of MIRAPEXIN prolonged-release tablets over placebo was demonstrated after 18 weeks of treatment on both the primary (UPDRS Parts II+III score) and the key secondary (off-time) efficacy endpoints.
MIRAPEXIN tabletter bør synkes med vand, og kan både tages sammen med eller uden mad. 
The tablets should be taken orally, swallowed with water, and can be taken either with or without food.
• Hallucinationer (ser, hører eller føler ting, som ikke er der). 
MIRAPEXIN can cause hallucinations (seeing, hearing or feeling things that are not there).
Mirapexin kan gives, som monoterapi eller i kombination med levodopa i hele sygdomsforløbet herunder i de sene stadier, når virkningen af levodopa klinger af eller bliver ustabil, og svingninger i den terapeutiske virkning opstår. 
MIRAPEXIN is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on off” fluctuations).
Hvis yderligere dosisøgning er nødvendig, bør dosis øges med 0,26 mg pramipexolbase/uge op til en maksimal dosis på 1,57 mg pramipexolbase (2,25 mg salt)/dag. 
If a further dose increase is necessary, doses should be increased by 0.26 mg pramipexole base at weekly intervals up to a maximum dose of 1.57 mg pramipexole base (2.25 mg of salt) per day.
Hvis din nyresygdom er moderat, er startdosis oftest 1 MIRAPEXIN tablet á 0,088 mg 2 gange daglig. 
If you have moderate kidney disease, the usual starting dose is 1 tablet MIRAPEXIN 0.088 mg twice a day.
Bivirkningerne kan forekomme med en given hyppighed, som defineres på følgende måde: Meget almindelig Kan forekomme hos flere end 1 ud af 10 patienter Almindelig 
Very common may affect more than 1 in 10 people Common may affect up to 1 in 10 people
Skema for øgning af dosis for Mirapexin depottabletter Uge Døgndosis (mg base) Døgndosis (mg salt) 
Ascending dose schedule of MIRAPEXIN prolonged-release tablets Week Daily dose (mg of base)
Ikke kendt: - Efter at du er holdt op med eller har reduceret din MIRAPEXIN-behandling: Depression, apati, angst, træthed, svedtendens eller smerter kan forekomme (kaldet dopaminagonistabstinenssyndrom eller DAWS). 
Not known: - After stopping or reducing your MIRAPEXIN treatment: Depression, apathy, anxiety, fatigue,
Almindeligste bivirkninger ved Parkinsons sygdom De mest almindeligt ( 5%) rapportede bivirkninger hos patienter med Parkinsons sygdom, som oftere ses efter behandling med pramipexol end efter behandling med placebo er kvalme, dyskinesi, hypotension, svimmelhed, døsighed, søvnløshed, forstoppelse, hallucinationer, hovedpine og træthed. 
Parkinson's disease, most common adverse reactions The most commonly (≥ 5%) reported adverse drug reactions in patients with Parkinson's disease more frequent with pramipexole treatment than with placebo were nausea, dyskinesia, hypotension, dizziness, somnolence, insomnia, constipation, hallucination, headache and fatigue.
Kartoner indeholdende 1,3 eller 10 blisterkort (10, 30 eller 100 depottabletter). 
Cartons containing 1, 3 or 10 blister strips (10, 30 or 100 prolonged-release tablets).
Nervesystemet døsighed, svimmelhed, dyskinesi hovedpine somnolens (søvnlignende bevidsthedssvækkelse), pludselig opstået søvn, amnesi, hyperkinesi, synkope 
Nervous system disorders somnolence dizziness dyskinesia headache sudden onset of sleep amnesia hyperkinesia syncope
1 MIRAPEXIN tablet á 0,7 mg og 1 MIRAPEXIN tablet á 0,35 mg 3 gange om dagen 
1 tablet MIRAPEXIN 0.7 mg and 1 tablet MIRAPEXIN 0.35 mg three times a day
Indehaver af markedsføringstilladelsen Boehringer Ingelheim International GmbH D-55216 Ingelheim am Rhein Tyskland 
Boehringer Ingelheim International GmbH D-55216 Ingelheim am Rhein Germany
Almene symptomer og reaktioner på administrationsstedet træthed perifere ødemer 
General disorders and administration site conditions fatigue peripheral oedema
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) Mirapexin 0,26 mg depottabletter EU/1/97/051/013-015 
MARKETING AUTHORISATION NUMBER(S) MIRAPEXIN 0.26 mg prolonged-release tablets EU/1/97/051/013-015
• Ved kreatininclearance mindre end 20 ml/min bør Mirapexin gives som en enkeltdosis begyndende med 0,088 mg base (0,125 mg salt) per døgn. 
In patients with a creatinine clearance less than 20 ml/min, the daily dose of MIRAPEXIN should be administered in a single dose, starting at 0.088 mg of base (0.125 mg of salt) daily.
MIRAPEXIN 0,7 mg er hvide, runde og flade tabletter. 
MIRAPEXIN 0.7 mg tablets are white, of round shape, and flat.
B. BETINGELSER ELLER BEGRÆNSNINGER VEDRØRENDE UDLEVERING OG 
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
Ved fremskreden Parkinsons sygdom kan dyskinesi forekomme i optitreringsfasen med Mirapexin, når det gives i kombination med levodopa. 
In advanced Parkinson's disease, in combination treatment with levodopa, dyskinesia can occur during the initial titration of MIRAPEXIN.
Dopaminagonistabstinenssyndrom inklusive apati, angst, depression, træthed, svedtendens, smerter 
Dopamine agonist withdrawal syndrome including apathy, anxiety, depression, fatigue, sweating and pain
Ppramipexoldosis bør reduceres med 0,52 mg base (0,75 mg salt)/dag, indtil den daglige dosis er reduceret til 0,52 mg base (0,75 mg salt). 
Pramipexole should be tapered off at a rate of 0.52 mg of base (0.75 mg of salt) per day until the daily dose has been reduced to 0.52 mg of base (0.75 mg of salt).
Mirapexin 0,088 mg tabletter Mirapexin 0,18 mg tabletter Mirapexin 0,35 mg tabletter Mirapexin 0,7 mg tabletter 
MIRAPEXIN 0.088 mg tablets MIRAPEXIN 0.18 mg tablets MIRAPEXIN 0.35 mg tablets MIRAPEXIN 0.7 mg tablets
Pramipexoldosis bør reduceres med 0,54 mg base (0,75 mg salt)/dag, indtil den daglige dosis er reduceret til 0,54 mg base (0,75 mg salt). 
Pramipexole should be tapered off at a rate of 0.54 mg of base (0.75 mg of salt) per day until the daily dose has been reduced to 0.54 mg of base (0.75 mg of salt).
MIRAPEXIN bruges til behandling af voksne patienter med symptomer på Parkinsons sygdom. 
MIRAPEXIN is used to treat the symptoms of primary Parkinson's disease in adults.
MIRAPEXIN tabletter skal synkes hele med vand. 
Swallow the tablets whole with water.
Sådan skal du tage MIRAPEXIN 
How to take MIRAPEXIN
MIRAPEXIN 0,26 mg depottabletter MIRAPEXIN 0,52 mg depottabletter MIRAPEXIN 1,05 mg depottabletter MIRAPEXIN 1,57 mg depottabletter MIRAPEXIN 2,1 mg depottabletter MIRAPEXIN 2,62 mg depottabletter MIRAPEXIN 3,15 mg depottabletter pramipexol 
MIRAPEXIN 0.26 mg prolonged-release tablets MIRAPEXIN 0.52 mg prolonged-release tablets MIRAPEXIN 1.05 mg prolonged-release tablets MIRAPEXIN 1.57 mg prolonged-release tablets MIRAPEXIN 2.1 mg prolonged-release tablets MIRAPEXIN 2.62 mg prolonged-release tablets MIRAPEXIN 3.15 mg prolonged-release tablets
Afhængigt af den enkelte patients respons på behandlingen kan det anbefales, at levodopadosis reduceres både under dosisstigning og vedligeholdelsesbehandling med Mirapexin (se pkt. 
It is recommended that the dose of levodopa is reduced during both the dose escalation and the maintenance treatment with MIRAPEXIN, depending on reactions in individual patients (see section
MIRAPEXIN 0,088 mg tabletter MIRAPEXIN 0,18 mg tabletter MIRAPEXIN 0,35 mg tabletter MIRAPEXIN 0,7 mg tabletter pramipexol 
MIRAPEXIN 0.088 mg tablets MIRAPEXIN 0.18 mg tablets MIRAPEXIN 0.35 mg tablets MIRAPEXIN 0.7 mg tablets Pramipexole
Hvis du ikke kan undvære MIRAPEXIN, bør amningen stoppe. 
If use of MIRAPEXIN is unavoidable, breast-feeding should be stopped.
1 MIRAPEXIN 1,05 mg depottablet, ELLER 
One MIRAPEXIN 1.05 mg prolonged-release tablet, OR
Tegn på overdosering kan blandt andet være opkastning, rastløshed eller nogle af de andre bivirkninger, der er anført under pkt. 
- You may experience vomiting, restlessness, or any of the side effects as described in section 4
Der er set færre svingninger i plasmakoncentrationen for pramipexol i løbet af 24 timer for Mirapexin depottabletter givet en gang daglig end for Mirapexin tabletter givet 3 gange daglig. 
The once daily administration of MIRAPEXIN prolonged-release tablets causes less frequent fluctuations in the pramipexole plasma concentration over 24 hours compared to the three times daily administration of pramipexole immediate release tablets.
MIRAPEXIN 0,26 mg og 0,52 mg depottabletter er hvide til råhvide, runde og har facetslebne kanter. 
What MIRAPEXIN looks like and contents of the pack MIRAPEXIN 0.26 mg and 0.52 mg prolonged-release tablets are white to off-white, of round shape, and have bevelled edges.
Fortæl det til din læge, hvis du har eller har haft nogen af nedenstående sygdomme eller tilstande: 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Medicin mod psykiske lidelser (antipsykotika) må ikke tages sammen med MIRAPEXIN. 
You should avoid taking MIRAPEXIN together with antipsychotic medicines.
• Forandring af søvnmønster, såsom søvnløshed (insomni) og søvnighed 
Common: - Changes in sleep pattern, such as sleeplessness (insomnia) and sleepiness - Tiredness (fatigue) - Headache - Abnormal dreams - Constipation - Dizziness - Vomiting (being sick)
Mirapexin 2,62 mg depottabletter EU/1/97/051/031-033 
MIRAPEXIN 2.62 mg prolonged-release tablets EU/1/97/051/031-033
Et fase-I studie, hvor pramipexoltabletter blev sammenlignet med pramipexoldepottabletter, viste ækvivalens mellem den samme døgndosis af Mirapexin depottabletter givet en gang daglig og Mirapexin tabletter givet 3 gange daglig for Cmin, Cmax og AUC. 
In a Phase I trial, where pramipexole immediate release and prolonged-release tablets were assessed in fasted state, the minimum and peak plasma concentration (Cmin, Cmax) and exposure (AUC) of the same daily dose of MIRAPEXIN prolonged-release tablets given once daily and MIRAPEXIN tablets given three times a day were equivalent.
Klinisk virkning og sikkerhed ved Parkinsons sygdom Hos patienter reducerer pramipexol tegn og symptomer på idiopatisk Parkinsons sygdom. 
In patients pramipexole alleviates signs and symptoms of idiopathic Parkinson's disease.
Afhængigt af patientens terapeutiske respons kan dosis af Mirapexin depottabletter justeres efterfølgende (se pkt. 
After switching to MIRAPEXIN prolonged-release tablets, the dose may be adjusted depending on the patient's therapeutic response (see section 5.1).
Hvis din nyresygdom er alvorlig, er startdosis oftest 1 MIRAPEXIN tablet á 0,088 mg 1 gang daglig. 
In severe kidney disease, the usual starting dose is just 1 tablet MIRAPEXIN 0.088 mg a day.
1 MIRAPEXIN tablet á 0,35 mg 
1 tablet MIRAPEXIN 0.35 mg
• Hvis nyrefunktionen bliver nedsat under vedligeholdelsesbehandling med Mirapexin, bør dosis reduceres med samme procent, som faldet i kreatininclearance. 
If renal function declines during maintenance therapy the MIRAPEXIN daily dose should be reduced by the same percentage as the decline in creatinine clearance, i.e. if creatinine clearance declines by 30%, then the MIRAPEXIN daily dose should be reduced by 30%.
Mirapexin 0,35 mg tabletter EU/1/97/051/011-012 
MIRAPEXIN 0.35 mg tablets EU/1/97/051/011-012
Kan forekomme hos mellem 1 og 10 ud af 10.000 patienter Meget sjælden Kan forekomme hos færre end 1 ud af 10.000 patienter Ikke kendt 
Very rare may affect up to 1 in 10,000 people
2 MIRAPEXIN tabletter á 0,088 mg 3 gange om dagen 
2 tablets MIRAPEXIN 0.088 mg three times a day
Mirapexin 0,088 mg tabletter EU/1/97/051/001-002 
MIRAPEXIN 0.088 mg tablets EU/1/97/051/001-002
Mirapexin 0,088 mg tabletter 
MIRAPEXIN 0.088 mg tablets
Skema til øgning af dosis for Mirapexin Titreringstrin 1 gang daglig Aften dosis (mg af base) 
Dose Schedule of MIRAPEXIN Titration Step Once Daily Evening Dose
Mirapexin 0,7 mg tabletter EU/1/97/051/005-006 
MIRAPEXIN 0.7 mg tablets EU/1/97/051/005-006
Mirapexin 0,35 mg tabletter 
MIRAPEXIN 0.35 mg tablets
(mg af salt) 
(mg of base)
Derefter bør dosis reduceres med 0,264 mg base (0,375 mg salt)/dag (se pkt. 
Thereafter the dose should be reduced by 0.264 mg of base (0.375 mg of salt) per day (see section 4.4).
Mirapexin 2,62 mg depottabletter 
MIRAPEXIN 2.62 mg prolonged-release tablets
MIRAPEXIN depottabletter skal tages en gang daglig. 
Take MIRAPEXIN prolonged-release tablets only once a day and each day at about the same time.
INFORMATION I BRAILLESKRIFT MIRAPEXIN 2,62 mg depottabletter 
INFORMATION IN BRAILLE MIRAPEXIN 2.62 mg prolonged-release tablets
Mirapexin 0,18 mg tabletter EU/1/97/051/003-004 
MIRAPEXIN 0.18 mg tablets EU/1/97/051/003-004
LÆGEMIDDELFORM OG INDHOLD (PAKNINGSSTØRRELSE) 10 depottabletter 
PHARMACEUTICAL FORM AND CONTENTS 10 prolonged-release tablets 30 prolonged-release tablets 100 prolonged-release tablets
2 MIRAPEXIN tabletter á 0,18 mg 3 gange om dagen 
2 tablets MIRAPEXIN 0.18 mg three times a day
Mirapexin 0,52 mg depottabletter EU/1/97/051/016-018 
MIRAPEXIN 0.52 mg prolonged-release tablets EU/1/97/051/016-018
• quinin (medicin til forebyggelse af smertefulde natlige lægkramper og til behandling af en malariatype kendt som falciparum malaria (ondartet malaria)) 
Take care if you are taking the following medicines: - cimetidine (to treat excess stomach acid and stomach ulcers) - amantadine (which can be used to treat Parkinson's disease) - mexiletine (to treat irregular heartbeats, a condition known as ventricular arrhythmia) - zidovudine (which can be used to treat the acquired immune deficiency syndrome (AIDS), a disease of the human immune system) - cisplatin (to treat various types of cancers) - quinine (which can be used for the prevention of painful night-time leg cramps and for the treatment of a type of malaria known as falciparum malaria (malignant malaria)) - procainamide (to treat irregular heart beat)
Børn og unge Børn og unge under 18 år bør ikke bruge MIRAPEXIN. 
Children and adolescents MIRAPEXIN is not recommended for use in children or adolescents under 18 years.
Derefter bør dosis reduceres med 0,26 mg base (0,375 mg salt)/dag (se pkt. 
Thereafter the dose should be reduced by 0.26 mg of base (0.375 mg of salt) per day (see section 4.4).
1 MIRAPEXIN tablet á 0,35 mg 3 gange om dagen 
1 tablet MIRAPEXIN 0.35 mg three times a day OR
Mirapexin 0,7 mg tabletter 
MIRAPEXIN 0.7 mg tablets
Bivirkninger som søvnighed og pludselig indsættende søvn er set specielt for Parkinsonpatienter. 
MIRAPEXIN has been associated with sleepiness and episodes of suddenly falling asleep, particularly in patients with Parkinson's disease.
Mirapexin kan ved behandling af restless legs syndrom (RLS) seponeres uden aftrapning, idet den daglige dosis ikke vil overstige 0,54 mg base (0,75 mg salt). 
Since the daily dose for the treatment of Restless Legs Syndrome will not exceed 0.54 mg of base (0.75 mg of salt) MIRAPEXIN can be discontinued without tapering off.
INFORMATION I BRAILLESKRIFT MIRAPEXIN 3,15 mg depottabletter 
INFORMATION IN BRAILLE MIRAPEXIN 3.15 mg prolonged-release tablets
INFORMATION I BRAILLESKRIFT MIRAPEXIN 0,088 mg 
INFORMATION IN BRAILLE MIRAPEXIN 0.088 mg
Mirapexin 1,05 mg depottabletter 
MIRAPEXIN 1.05 mg prolonged-release tablets
Mirapexin 3,15 mg depottabletter 
MIRAPEXIN 3.15 mg prolonged-release tablets
Det skal du vide, før du begynder at tage MIRAPEXIN Sådan skal du tage MIRAPEXIN Bivirkninger 
What MIRAPEXIN is and what it is used for What you need to know before you take MIRAPEXIN How to take MIRAPEXIN
INFORMATION I BRAILLESKRIFT MIRAPEXIN 0,26 mg depottabletter 
INFORMATION IN BRAILLE MIRAPEXIN 0.26 mg prolonged-release tablets
Mirapexin 0,18 mg tabletter 
MIRAPEXIN 0.18 mg tablets
• Lavt blodtryk (hypotension) 
This is to avoid postural hypotension (a fall in blood pressure on standing up).
Dosis bør nedsættes, når du starter behandling med MIRAPEXIN. 
You should have regular eye examinations during treatment with MIRAPEXIN.
INFORMATION I BRAILLESKRIFT MIRAPEXIN 1,05 mg depottabletter 
INFORMATION IN BRAILLE MIRAPEXIN 1.05 mg prolonged-release tablets
Mirapexin 1,57 mg depottabletter 
MIRAPEXIN 1.57 mg prolonged-release tablets
Mirapexin 1,05 mg depottabletter EU/1/97/051/019-021 
MIRAPEXIN 1.05 mg prolonged-release tablets EU/1/97/051/019-021
Mirapexin 3,15 mg depottabletter EU/1/97/051/025-027 
MIRAPEXIN 3.15 mg prolonged-release tablets EU/1/97/051/025-027
EU/1/97/051/022-024 
EU/1/97/051/002 [100 tablets]
Mirapexin 0,7 mg tabletter Hver tablet indeholder 1,0 mg pramipexol dihydrochloridmonohydrat svarende til 0,7 mg pramipexol. 
MIRAPEXIN 0.26 mg prolonged-release tablets Each prolonged-release tablet contains 0.375 mg pramipexole dihydrochloride monohydrate equivalent to 0.26 mg pramipexole.
INFORMATION I BRAILLESKRIFT MIRAPEXIN 0,35 mg 
INFORMATION IN BRAILLE MIRAPEXIN 0.35 mg
INFORMATION I BRAILLESKRIFT MIRAPEXIN 0,52 mg depottabletter 
INFORMATION IN BRAILLE MIRAPEXIN 0.52 mg prolonged-release tablets
Mirapexin 1,57 mg depottabletter EU/1/97/051/028-030 
MIRAPEXIN 1.57 mg prolonged-release tablets EU/1/97/051/028-030
INFORMATION I BRAILLESKRIFT MIRAPEXIN 1,57 mg depottabletter 
INFORMATION IN BRAILLE MIRAPEXIN 1.57 mg prolonged-release tablets
Hver tablet indeholder 0,125 mg pramipexol dihydrochloridmonohydrat svarende til 0,088 mg pramipexol. 
Each tablet contains 0.125 mg pramipexole dihydrochloride monohydrate equivalent to 0.088 mg pramipexole.
1 MIRAPEXIN tablet á 0,088 mg 
1 tablet MIRAPEXIN 0.088 mg
1 MIRAPEXIN tablet á 0,18 mg 
1 tablet MIRAPEXIN 0.18 mg
3 MIRAPEXIN tabletter á 0,18 mg 
3 tablets MIRAPEXIN 0.18 mg
INFORMATION I BRAILLESKRIFT MIRAPEXIN 2,1 mg depottabletter 
INFORMATION IN BRAILLE MIRAPEXIN 2.1 mg prolonged-release tablets
1 MIRAPEXIN tablet á 0,18 mg 3 gange om dagen 
1 tablet MIRAPEXIN 0.18 mg three times a day OR
2 MIRAPEXIN tabletter á 0,18 mg 
2 tablets MIRAPEXIN 0.18 mg
LÆGEMIDLETS NAVN MIRAPEXIN 2,62 mg depottabletter pramipexol 
NAME OF THE MEDICINAL PRODUCT MIRAPEXIN 2.62 mg prolonged-release tablets Pramipexole